The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Teclistamab for multiple myeloma in US hospitals: real-world data analysis
Carlyn Tan, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses an updated analysis of data from a real-world, retrospective study looking at the patient profiles and step-up dosing process of early initiators of teclistamab for multiple myeloma in the US. The Premier Healthcare Database was used, with a total of 113 patients included in this study. This analysis confirmed that these patients were diverse, elderly, and were able to complete the step-up dosing process during one hospitalization. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Sanofi, Janssen
Current Employment: Janssen
Research Funding: Janssen, Takeda
